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Cost-Effectiveness of Multidisciplinary Management and Exercise Training in Heart
Failure Treatment
Anji Yi
Introduction
As one of the major public health problems, heart failure (HF) is affecting more than
3 million patients in the United States [1]. Around 20% of all hospitalizations in
populations older than 60 years of age in developed countries are caused or
complicated by HF [2]. HF has been incurring above $38 billion annual health care
expenditures a year, of which $23 billion is for hospital stays [3], accounting for 1-2% of
total health care expenditure [4] and two third of hospitalization costs in the United
States and Europe [5]. HF not only ranks the first in the most common discharge
diagnoses among elderly patients, and shows extremely high readmission rates after
index hospitalization, with up to 44% of patients re-hospitalized within six months of
discharge [6].
In addition to pharmacologic treatments, several behavioral interventions have
been receiving more attention and documented to improve quality of life and reduce
hospitalization of HF patients [7]. The major interventions reported include
multidisciplinary management programs (MMP) [8] and exercise training programs
(ETP) [9], and both of these two methods have been proved to be effective in improving
the survival of HF patients. One [10] cost-effectiveness analysis, based on a systematic
literature review of clinical trials on MMP [5], estimated an incremental costeffectiveness ratio (ICER) of $9,700 per life-year gained in MMP as compared to usual
care (UC). There are two published cost-effectiveness analyses on exercise training
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based on two clinical trials [11, 12], respectively, and the ICERs were $1,773 and
$26,462 per life-year saved, respectively. However, no comparison has been made
between the cost-effectiveness of the MMP and ETP; thus it is still unclear that which
one is more desirable in terms of the cost-effectiveness in HF treatment. Therefore, a
cost-effectiveness analysis comparing these two interventions is needed to determine
the most cost-effective intervention for HF patients.

Methods
Study population and interventions
We used published data from several literature reviews of randomized controlled trials
on MMP and ETP, as shown in Table 1. The study population in the used studies was
patients aged 56-80 years old with heart failure diagnosed from hospital in North America,
Europe, Australia, or New Zealand. The key components of MMP included disease
education for patients and continuing support, such as psychological support, dietary and
social services consultation, and regular follow-ups by nurse, primary care physician, or
pharmacist, or through telephone [5]. While ETP, as explained by the name itself, focused
on frequent hospital-based exercise training, under the supervision of professional medical
exercise trainer, as well as regular cardiopulmonary stress test during the training and
basic components of MMP [13]. Therefore, ETP included exercise training in addition to the
management care provided by MMP.

Structure of the model
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Figure 1. Markov model diagram. Patients occupy and transit among Markov states,
including living, hospitalization, living after hospitalization, and death.

We developed a Markov model with eight transitional states to simulate long-term
follow-ups. In this model, the patient population occupies eight states—four living states,
three hospitalization states, and a death state. The living states and hospitalization states
were classified by the number of previous hospitalizations, which has been proved to be a
significant risk factor for HF re-hospitalization and mortality [14]. Figure 1 presented the
schematic view of the Markov model.
The model starts with HF patients under a stable condition, and then moving through
subsequent cycles of being alive, hospitalized, or dead. The cycle length is one month. We
selected time horizon of 10 years as most of our cohort died within 8 years. At the end of
each month, patients transited into the next state, according to the transitional
probabilities of hospitalization and death at the current state. Patients in states other than
death might continue to live, get hospitalized, or die from cardiovascular or noncardiovascular causes at the next cycle. We assumed that the relative risks (RRs) in each
intervention program compared to UC stay consistent, and the risks of hospitalization and
mortality become constant after 3 times of hospitalization.
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Input data
The input parameters were derived from literature reviews (Table 1). To examine the
cost-effectiveness of MMP and ETP in HF, several groups of input data were needed—
hospitalization rate and mortality rate in UC at a living state with no previous
hospitalization, in-hospital mortality rate with no previous hospitalization, relative risks
(RRs) of hospitalization and mortality in MMP and ETP comparing to the risks in UC, RRs of
hospitalization and mortality with previous hospitalizations comparing to the risks without
previous hospitalization, and costs of UC, MMP, and ETP. The costs of intervention
programs incurred at the beginning of the follow-up, the costs of hospitalization incurred at
every hospitalization, and the costs of outpatient care and wage losses were counted
continuously throughout the follow-up. We assumed the costs of outpatient care, which
was one of the major costs in UC, were the same in the three programs, as the the
components in UC were also contained in the intervention programs. Wage loss only
occurred in ETP, since patients in this program have lost working hours for exercising. A
discount rate of 5% was used to calculate total costs, which were converted to the amount
incurred at the beginning of follow-up. The input data used in this study came from the
results of several published literature reviews, as shown in Table 1. The original
hospitalization and mortality rates from the reviews were converted into monthly
probabilities to perform the analyses.

Estimate

95% confidence
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interval
Hospitalization rate with no previous hospitalization
UC [10]

0.008

0.006 – 0.011

RR of hospitalization with previous hospitalizations [14]
1*

1.28

1.23 – 1.33

2

3.32

3.21 – 3.43

0.007

0.006 – 0.009

0.154

0.105 – 0.202

Mortality rate with no previous hospitalization
UC [10]
In hospital mortality
UC [15]

RR of mortality with previous hospitalizations [16]
1

1.22

1.14 – 1.30

2

1.33

1.20 – 1.47

3

1.64

1.40 – 1.91

MMP [5]

0.73

0.66 – 0.82

ETP [17]

0.61

0.46 – 0.80

MMP [5]

0.83

0.70 – 0.99

ETP [9]

0.64

0.40 – 1.02

RR of hospitalization

RR of mortality

Costs ($/patient) **

5

MMP implementation costs [10]

826

660 – 991

ETP implementation costs [13]

2,020

1,610 – 2,428

Outpatient HF care costs for all [10]

1,871

1,497 – 2,245

Wage loss in ETP [13]

3,648

2,918 – 4,378

Hospitalization cost per stay [13]

11,413

9,130 – 13,696

Table 1. Input data: probabilities, RRs, and costs.
* Number of previous hospitalizations
** All costs are converted into 2015 U.S. dollar.
*** The total costs of interventions are the costs of intervention programs plus the cost of
UC.

Cost-effectiveness analysis and sensitivity analyses
The life-years of patients and corresponding costs in each group were obtained. We
calculated ICERs as cost per life-year saved. Sensitivity analyses were performed to
examine the robustness of the results and address the uncertainty in the input data. We
conducted one-way sensitivity analysis on the variables within clinically plausible ranges
on our baseline estimates (Table 1). In the probabilistic sensitivity analysis, Monte Carlo
simulation, implemented with Metropolis-Hasting algorithm [18], was used to generate
10,000 trials of follow-ups, in which each parameter was sampled from a specified
distribution (beta distribution for probabilities and log-normal distribution for RRs) within
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its plausible range. Each trial yielded an ICER for each comparison pairs, and the
distributions of the ICERs and the cost-acceptance curve from the 10,000 trials were
examined at the end.

Results
Base-case analysis
UC
Costs ($)
Live-year saved
Incremental costs ($)
Incremental life-year saved
Incremental C/E ($/life-year saved)

MMP1

ETP2

10,694

12,007

37,635

6.75

7.12

7.93

1,313

25,628

0.37

0.81

3,535

31,624

Table 2. Cost-effectiveness of MMP and ETP.
1: MMP vs. UC
2: ETP vs. MMP

Table 2 summarizes aggregate results out of a possible patient population under UC,
MMP, and ETP for a 10-year follow-up period. Patients under UC lived an average of 6.75
years and accrued $10,694 in healthcare cost per patient. Under intervention programs,
these same patients lived an average of 7.12 years per patient in MMP and 7.93 years per
patient in ETP, and cost $12,007 per patient in MMP and $37,635 per patient in ETP.
Therefore, MMP increased the patients’ life expectancy by 0.37 years per patient with an
additional $13,13 of healthcare costs per patient as compared to UC, and ETP achieved a
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0.81-year of life-year increase for $25,628 additional cost per patient as compared to MMP.
The ICERs were $3,535 per life-year saved in MMP compared to UC and $31,624 per lifeyear saved in ETP compared to MMP.

One-way sensitivity analysis
One-way sensitivity analysis
UC vs. MMP

ICER ($/Life-year saved)
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One-way sensitivity analysis
MMP vs. ETP

ICER ($/Life-year saved)

Figure 2. One-way sensitivity analysis.

Figure 2 shows the one-way sensitivity analysis, in which one of the input parameters
was changed each time, within its plausible range. The ICER of MMP as compared to UC
ranged from $1,307 to $4,743 per life-year saved, with the parameter change in either UC
or MMP. The ICER of ETP as compared to MMP ranged from $16,043 to $42,397 per lifeyear saved, with the parameter change in either MMP or ETP.
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Probabilistic sensitivity analysis

Figure 3. Cost-effectiveness acceptability curve

In the probabilistic sensitivity analysis, the median ICER of MMP comparing to UC was
$3,718 per life-year saved, and the median ICER of ETP comparing to MMP was $30,006
per life-year saved. The cost-effectiveness acceptability curves (Figure 3) show that UC is
the most cost-effective option when the willingness to pay is lower than $4,050 per lifeyear saved, MMP becomes the most cost-effective one when the budget is more than $4,015
but less than $29,697, and when the budget is more than $29,697 per life-year saved, ETP
is the most cost-effective strategy.
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Discussion
MMP has been a widely studied and adopted intervention program that provides HF
patients continuous disease education, as well as social and psychological support. ETP
serves as a more advanced intervention program that integrates the basic elements in MMP
with regular exercise training to improve HF prognosis. There is evidence from multiple
resources that MMP and ETP can increase the survival of HF patients in a cost-effective way
by reducing hospitalization and mortality [5, 11, 19, 20]. However, the cost-effectiveness of
the two intervention programs was studied individually and no direct comparison has been
made between them.
This study confirmed the cost-effectiveness of MMP and ETP for treating HF patients.
MMP was found to prolong the survival of HF patients and at an expected cost of $3,535 per
life-year saved, and ETP further increased survival at an expected cost of $31,624 per lifeyear saved. With an incremental survival of 0.81 years as compared to MMP, ETP yielded
much higher costs due to the wage loss, in addition to the costs of implementing the
program, of patients participated in the program, which were not offset by the reduced
hospital costs. Nevertheless, the results of both the two intervention programs lie within a
reasonable range of cost-effectiveness in improving HF patients’ survival. Furthermore, this
analysis used life-year saved as the effectiveness measurement and did not incorporate
quality of life, while evidences have been showing that MMP and ETP improve quality of life
in HF patients; our estimates are therefore conservative in assessing the effectiveness of
the two intervention programs[5, 17]. To our knowledge, this is by far the first analysis that
took the two intervention programs together into consideration and assessed the cost-
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effectiveness acceptability of the programs, so that provided more nuanced information for
deciding an optimal intervention for HF patients given a broad range of willing-to-pay
threshold.
There are still some limitations in this analysis due to the data source and model
assumptions. First of all, the input data of the three arms (UC, MMP, and ETP) in this
analysis came from multiple literature reviews [5, 9, 10, 13, 17], therefore it is possible that
the HF patients from these different sources were not exactly under the same condition
when being included in the study. The hospitalization and mortality data of MMP came
from the same review study [5], while the data of ETP were extracted from two studies [9,
17], since neither of the two studies alone provided complete input data for our analysis.
The study populations were all elder HF patients in developed countries, but some
demographic factors, such like gender, race, income, and education level, were not adjusted
and might have generated differences in the outcomes among those patients. This analysis
assumed that MMP and ETP applied to the same group of patients, while it is possible that
some HF patients in severer conditions were not able to take ETP but could only accept
MMP. The study population in ETP reviews was patients with low-to-medium risk (New
York Heart Association (NYHA) class II and III) and at a median age of 60 [17], while the
population in MMP studies was HF patients discharged from hospital and at a median age
of 70 [5]. In that case, patients who were able to participate in ETP were healthier, younger,
and at lower risks of hospitalization and death compared to those who took MMP, posing a
potential bias in this comparison between MMP and ETP. These limitations might affect the
generalization of the results in this analysis, and further studies are needed to generate
more valid data source and more robust analytical models.
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Conclusion
This cost-effectiveness analysis confirms the improvement in survival of HF patients
under MMP and ETP, and compares the cost-effectiveness and acceptability of the two
programs. ETP generated higher life-year saving for higher costs than MMP did. MMP was
the most cost-effective way with low willing-to-pay threshold (between $4,015 and
$29,697 per life-year saved), while ETP was reasonably cost-effective when the society is
willing to pay more than $29,697 per life-year saved.
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